Merz Pharma Group has entered into a definitive agreement with Swiss dermatology company Neocutis to acquire the privately held company’s cosmetics, OTC and Rx skin care business, which includes Neocutis, a line of physician-dispensed topical skin care products sold in the US.
“Neocutis is an innovative company with an excellent presence in the US market, and a promising potential for development,” said Philip Burchard, CEO of Merz Pharma Group. “This transaction is an important step to expand our US business, as Neocutis products are an excellent addition to our own aesthetics portfolio.”
According to Merz, the acquisition reflects a strategy to establish itself as a global leader in medical and aesthetic dermatology. Merz North America offers dermal fillers such as Radiesse Volumizing Filler, as well as Mederma, a skin care line for scar care and stretch marks therapy.
Neocutis S.A. was founded in February 2003 as a spin-off of the medical faculty of the Lausanne University Clinic, Switzerland. The privately owned company is headquartered in Lausanne, Switzerland and develops and distributes innovative cosmetic products for dermatologic conditions and anti-aging skin care. The company entered the US market in 2009 and since that time has seen double-digit growth annually, according to Merz.